The use of telemedicine to aid in the assessment of patients with tardive dyskinesia has emerged. Here are my key insights on how it could be used.
Early recognition of signs and symptoms potentially associated with TD can lead to improved understanding of the diagnosis, consideration of treatment options, and better long-term patient outcomes. Here are my key insights on TD identification.
Anticholinergics improve parkinsonism but exacerbate TD, and VMAT2 inhibitors improve TD but do not treat parkinsonism and may worsen it. Jonathan Meyer, MD, explores this psychopharmacology topic and reflects on processes acting on different neurons.
Tardive dyskinesia (TD) has a real-world impact on patient lives. Greg Mattingly, MD, explores the social and emotional impact of TD on patients as well as its prevalence and diagnosis.
The availability of 2 FDA-approved agents for the treatment of tardive dyskinesia has been a tremendous accomplishment. In this ClinicalThought, I explore the choices of FDA-approved agents to treat tardive dyskinesia and review what to consider.
The burden of schizophrenia and tardive dyskinesia is extensive. In this expert commentary, Martha Sajatovic, MD, explores the American Psychiatric Association 2021 practice guidelines on tardive dyskinesia management in schizophrenia and the advancements in pharmacologic and psychosocial treatments.